COMPANY

Aitia

Uses causal AI, human multiomics data and its Gemini Digital Twins to accelerate the discovery of therapeutics with biopharma partners. Source

Keywords: causal AI multiomics Gemini Digital Twins

Profile checked Oct 10, 2026

Raises and deals from press releases

Deal Deal · amount not disclosed · announced Oct 30, 2024 Company release ↗
Source quote
- Oct 30, 2024 · Company release ↗
  “Somerville, MA, Oct. 30, 2024: Aitia, a biotech company pioneering the use of causal AI and Digital Twins in drug discovery and development, is expanding its collaboration with Servier, a global and independent pharmaceutical company, to tackle gliomas, a broad group of brain cancers.”
Deal Deal · amount not disclosed · announced Jan 8, 2024 Company release ↗
Source quote
- Jan 8, 2024 · Company release ↗
  “Aitia‘s Gemini Digital Twins will help identify subpopulations of patients who could respond favorably to Servier’s LRRK2 in development treatment Suresnes (France), 08 January 2024 – Servier, an independent international pharmaceutical group, and Aitia, the leader in the application of causal AI”

From the company’s own releases; this list is partial. All raises and deals

Sep 1, 2026 Partnership Partnership / licensing announced Sep 1, 2026. Source: company's own press page. source ↗
Oct 30, 2024 Partnership Partnership / licensing announced Oct 30, 2024. Source: company's own press page. source ↗

Last 2 years.

Sep 1, 2026 Partnership / licensing announced Sep 1, 2026. Source: company's own press page. source ↗
Oct 30, 2024 Partnership / licensing announced Oct 30, 2024. Source: company's own press page. source ↗

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-14